This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ARNA Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Arena Pharmaceuticals Stock (NASDAQ:ARNA) 30 days 90 days 365 days Advanced Chart Get Arena Pharmaceuticals alerts:Sign Up Key Stats Today's Range$99.99▼$99.9950-Day Range$93.13▼$99.9952-Week Range$45.50▼$100.00Volume107 shsAverage Volume1.56 million shsMarket Capitalization$6.17 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc. Read More Receive ARNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARNA Stock News HeadlinesNeuvivo makes bid to enter ALS arena with immunotherapy candidateOctober 7, 2024 | msn.comArwana Citramulia Tbk (ARNA)August 31, 2023 | uk.investing.com[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to two crypto experts, that moment is here. Their Crypto Code Workshop shows how to get positioned before altcoins take off, ride the wave, and lock in gains — with a free $10 Bitcoin bonus just for attending. | Crypto Swap Profits (Ad)MLS club places Bruce Arena on leave over probe into 'allegations of insensitive and inappropriate remarks'August 21, 2023 | foxnews.comRNA startup launches with $300M, Merck partnershipMay 23, 2023 | bizjournals.comLongboard Pharmaceuticals: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023May 23, 2023 | seekingalpha.comPfizer earnings and revenue top expectations despite Covid vaccine sales declineMay 6, 2023 | cnbc.comArna L. DavidsonApril 25, 2023 | health.usnews.comSee More Headlines ARNA Stock Analysis - Frequently Asked Questions How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share for the quarter, missing the consensus estimate of ($2.53) by $0.68. When did Arena Pharmaceuticals' stock split? Shares of Arena Pharmaceuticals reverse split on the morning of Monday, June 19th 2017.The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Arena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Cytokinetics (CYTK), Micron Technology (MU), Bristol Myers Squibb (BMY) and Canopy Growth (CGC). Company Calendar Last Earnings11/04/2021Today7/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ARNA CIK1080709 Webwww.arenapharm.com Phone(858) 453-7200Fax858-453-7210Employees448Year Founded1977Profitability EPS (Trailing Twelve Months)($10.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$616.43 million Net MarginsN/A Pretax Margin-1,141,542.63% Return on Equity-69.83% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.05 Current Ratio8.59 Quick Ratio8.59 Sales & Book Value Annual Sales$50 thousand Price / Sales123,305.67 Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book9.14Miscellaneous Outstanding Shares61,659,000Free Float60,173,000Market Cap$6.17 billion OptionableOptionable Beta0.55 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ARNA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arena Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.